CRIS Current Research Information System

GAMBINERI, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.884
EU - Europa 3.624
AS - Asia 1.090
AF - Africa 221
SA - Sud America 25
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 4
Totale 9.861
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.870
GB - Regno Unito 925
IT - Italia 713
DE - Germania 483
SE - Svezia 457
CN - Cina 444
VN - Vietnam 306
IN - India 246
RU - Federazione Russa 189
UA - Ucraina 183
IE - Irlanda 172
FR - Francia 148
TG - Togo 83
ZA - Sudafrica 82
CH - Svizzera 67
EE - Estonia 66
BG - Bulgaria 58
FI - Finlandia 36
AT - Austria 27
NL - Olanda 25
CI - Costa d'Avorio 22
NG - Nigeria 22
SG - Singapore 18
JO - Giordania 16
BE - Belgio 14
AL - Albania 11
AU - Australia 11
BR - Brasile 11
IR - Iran 11
SC - Seychelles 11
CA - Canada 10
GR - Grecia 9
JP - Giappone 9
PH - Filippine 9
RO - Romania 7
DK - Danimarca 6
HR - Croazia 6
BD - Bangladesh 5
NO - Norvegia 5
PE - Perù 5
CL - Cile 4
ES - Italia 4
EU - Europa 4
HK - Hong Kong 4
LB - Libano 4
TW - Taiwan 4
AR - Argentina 3
KR - Corea 3
KZ - Kazakistan 3
MD - Moldavia 3
PT - Portogallo 3
BA - Bosnia-Erzegovina 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
NZ - Nuova Zelanda 2
AE - Emirati Arabi Uniti 1
BO - Bolivia 1
BZ - Belize 1
EG - Egitto 1
FK - Isole Falkland (Malvinas) 1
ID - Indonesia 1
LA - Repubblica Popolare Democratica del Laos 1
MX - Messico 1
MY - Malesia 1
PL - Polonia 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 9.861
Salva come PNG Salva come JPEG
Città #
Southend 835
Fairfield 740
Chandler 406
Ashburn 374
Woodbridge 368
Seattle 328
Houston 321
Wilmington 318
Bologna 243
Princeton 231
Dong Ket 225
Ann Arbor 217
Cambridge 209
Dublin 172
Jacksonville 117
Westminster 98
Nanjing 88
Lomé 83
Padova 83
Berlin 75
Bern 58
Sofia 58
Saint Petersburg 54
San Diego 44
Shenyang 41
Redwood City 39
Beijing 36
Helsinki 36
Hebei 35
Redmond 35
Jinan 34
Bremen 33
Milan 32
New York 32
Changsha 29
Mülheim 29
Nanchang 25
Norwalk 25
Turin 25
Vienna 24
Abeokuta 22
Abidjan 22
Dearborn 22
Falls Church 22
Tianjin 22
Guangzhou 21
Des Moines 20
Olalla 19
Amman 16
Jiaxing 15
Boardman 13
Brussels 13
Haikou 13
Hyderabad 13
Medford 12
Vicenza 12
Zhengzhou 12
Los Angeles 11
Dronten 10
Mahé 10
Rome 10
Singapore 10
Durrës 9
Lanzhou 9
Ningbo 9
San Venanzo 9
Taizhou 9
Boydton 8
Modena 7
Taiyuan 7
Buffalo 6
Hangzhou 6
Paris 6
San Jose 6
São Paulo 6
Verona 6
Wuhan 6
Bühl 5
Cento 5
Cesena 5
Costa Mesa 5
Frankfurt Am Main 5
Frankfurt am Main 5
Kuban 5
Lima 5
London 5
Phoenix 5
Tokyo 5
Valsamoggia 5
Catanzaro 4
Davao City 4
Forlì 4
Kilburn 4
Kunming 4
Lausanne 4
Monterado 4
Monza 4
Mumbai 4
Napoli 4
Novate Milanese 4
Totale 6.808
Salva come PNG Salva come JPEG
Nome #
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial 224
Body mass index rather than the phenotype impacts precocious ultrasound cardiovascular risk markers in polycystic ovary syndrome 185
Defining hyperandrogenism in women with polycystic ovary syndrome: A challenging perspective 182
Behavioral, socio-environmental, educational and demographic correlates of excess body weight in Italian adolescents and young adults 169
17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. 167
Androgen Profiling by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) in Healthy Normal-Weight Ovulatory and Anovulatory Late Adolescent and Young Women 158
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. 153
A new interaction to come: Ghrelin and steroid hormones 150
Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning 148
Plasma 2-arachidonoylglycerol is a biomarker of age and menopause related insulin resistance and dyslipidemia in lean but not in obese men and women 135
New insights on diabetes in Turner syndrome: results from an observational study in adulthood 132
Sex hormones, obesity and type 2 diabetes: is there a link? 132
Anti-müllerian hormone and insulin-like 3 levels in healthy normal-weight ovulatory and anovulatory eumenorrheic late adolescent females: potential early biomarkers of ovarian dysfunction? 129
Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome 120
Short-term modification of sex hormones is associated with changes in ghrelin circulating levels in healthy normal-weight men. 119
Profiling plasma N-Acylethanolamine levels and their ratios as a biomarker of obesity and dysmetabolism 118
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. 113
The empowerment of translational research: lessons from laminopathies. 113
Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. 112
Common variants in the sex hormone-binding globulin gene (SHBG) and polycystic ovary syndrome (PCOS) in Mediterranean women. 112
Insulin sensitizers in polycystic ovary syndrome 111
Ghrelin and reproductive disorders. 110
Clinical assessment of allostatic overload in adolescent and young women with hyperandrogenic states 109
Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. 107
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. 106
Psychological aspects of hyperandrogenic states in late adolescent and young women. 106
The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk 105
Steroid biomarkers for identifying non-classic adrenal hyperplasia due to 21-hydroxylase deficiency in a population of PCOS with suspicious levels of 17OH-progesterone 104
Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. 103
Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors 103
A comprehensive approach in diagnosing the polycystic ovary syndrome 103
Impact of age, body weight and metabolic risk factors on steroid reference intervals in men 103
Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays and reference intervals in healthy adults. 102
In memoriam: Renato Pasquali (1946-2019) 102
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. 100
Maternal polycystic ovary syndrome may be associated with adverse pregnancy outcomes. 100
Targeting insulin sensitivity in the treatment of polycystic ovary syndrome 100
Salivary cortisol and cortisone responses to short-term psychological stress challenge in late adolescent and young women with different hyperandrogenic states 99
Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin 98
Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS 97
An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. 97
Revisiting hyper- and hypo-androgenism by tandem mass spectrometry. 96
Parallel variations of insulin-like peptide 3 (INSL3) and antimüllerian hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern. 96
null 96
Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study. 96
Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. 95
Familial partial lipodystrophy, mandibuloacral dysplasia and restrictive dermopathy feature barrier-to-autointegration factor (BAF) nuclear redistribution 95
Metabolic effects of obesity on reproduction. 94
Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls 93
Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome. 93
Female and male serum reference intervals for challenging sex and precursor steroids by liquid chromatography - tandem mass spectrometry 93
Role of changes in dietary habits in polycystic ovary syndrome. 91
Androgens and Severe Insulin Resistance States: Basic and Clinical Aspects 91
Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. 90
Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity 90
Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects 89
Obituary: Renato Pasquali (1946-2019) 89
No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours 88
High serum concentration of total inhibin in polycystic ovary syndrome 86
Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. 86
Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. 86
Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study 86
Sindrome dell'ovaio policistico e diabete di tipo 2 85
Prevalence of Hyperandrogenic States in Late Adolescent and Young Women: Epidemiological Survey on Italian High-School Students 85
null 85
Insulin-sensitizing agents in women with polycystic ovary syndrome. 83
Improving the diagnosis of 11β-hydroxylase deficiency using home-made MLPA probes: identification of a novel chimeric CYP11B2/CYP11B1 gene in a Sicilian patient 83
Insulin-sensitizing agents in polycystic ovary syndrome. 81
Hirsutism and virilization 79
Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome. 77
Mechanisms and treatment of obesity in polycystic ovary syndrome 77
Quality of diet, screened by the Mediterranean diet quality index and the evaluation of the content of advanced glycation endproducts, in a population of high school students from Emilia Romagna 77
null 77
Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors 76
The role of low-grade inflammation in the polycystic ovary syndrome. 75
MANAGEMENT OF ENDOCRINE DISEASE: Secondary polycystic ovary syndrome: theoretical and practical aspects. 74
Mitochondrial oxidative phosphorylation is impaired in patients with congenital lipodystrophy. 72
Involvement of the endocannabinoid system in metabolism and fertility 71
European survey of diagnosis and management of the polycystic ovary syndrome: Results of the ESE PCOS Special Interest Group's Questionnaire 71
Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. 71
Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. 70
Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome 69
Type 2 diabetes and the polycystic ovary syndrome. 69
null 68
Liraglutide and cardiovascular outcomes in type 2 diabetes 68
Response of the hypothalamic-pituitary-adrenal axis to small dose arginine-vasopressin and daily urinary free cortisol before and after alprazolam pre-treatment differs in obesity. 68
New perspectives on the definition and management of polycystic ovary syndrome 68
Glucose intolerance states in women with the polycystic ovary syndrome. 65
Insulin resistance, obesity and the metabolic syndrome in polycystic ovary syndrome. 62
Molecular and phenotypical characterization of 10 families with 11ß-hydroxylase deficiency 62
Functional effects of polymorphisms in the human gene encoding 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1): a sequence variant at the translation start of 11 beta-HSD1 alters enzyme levels. 59
The impact of obesity on reproduction in women with polycystic ovary syndrome. 56
Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE) 56
Biomediators in polycystic ovary syndrome and cardiovascular risk 55
Obesity and infertility 54
Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction 54
European lipodystrophy registry: Background and structure 53
Steroid reference intervals in women: influence of menopause, age and metabolism 51
The endocrine impact of obesity and body habitus in the polycistic ovary syndrome 50
Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions 50
Totale 9.561
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.777
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.777
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019112 0 0 0 0 0 0 0 0 0 0 0 112
2019/20202.780 375 61 27 160 287 283 363 382 367 180 121 174
2020/20211.592 309 108 49 86 30 142 35 108 157 90 74 404
2021/20221.999 161 57 119 132 193 94 71 165 73 134 478 322
2022/20232.170 233 295 93 305 148 131 69 114 350 165 158 109
2023/2024728 77 116 54 48 54 114 53 48 16 77 48 23
Totale 10.136